ESR1 and breast carcinoma: NCT00503841 aimed to estimate the effect of the EGF receptor inhibitor erlotinib on the expression of nuclear NFκB and amphiregulin in patients with ER-negative, EGFR-positive, and IL-1α-positive breast cancer.